Shares of Savara Inc (NASDAQ:SVRA) have been given an average recommendation of “Buy” by the seven analysts that are presently covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $18.00.

Several analysts have issued reports on the company. Zacks Investment Research lowered Savara from a “buy” rating to a “hold” rating in a research note on Friday, May 17th. Roth Capital set a $10.00 price objective on Savara and gave the company a “hold” rating in a research note on Tuesday, May 14th. ValuEngine upgraded Savara from a “sell” rating to a “hold” rating in a research note on Monday, April 1st. Finally, BidaskClub upgraded Savara from a “hold” rating to a “buy” rating in a research note on Friday, April 5th.

In other news, Director Richard J. Hawkins sold 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $11.10, for a total value of $277,500.00. Following the transaction, the director now owns 21,682 shares of the company’s stock, valued at $240,670.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO David L. Lowrance sold 7,500 shares of the company’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $9.02, for a total value of $67,650.00. Following the completion of the transaction, the chief financial officer now directly owns 2,446 shares in the company, valued at approximately $22,062.92. The disclosure for this sale can be found here. Insiders sold 75,261 shares of company stock worth $744,174 in the last ninety days. 6.50% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the company. MetLife Investment Advisors LLC bought a new position in shares of Savara during the 1st quarter worth approximately $116,000. Metropolitan Life Insurance Co NY bought a new position in shares of Savara during the 1st quarter worth approximately $83,000. Geode Capital Management LLC lifted its position in shares of Savara by 5.5% during the 1st quarter. Geode Capital Management LLC now owns 327,537 shares of the company’s stock worth $2,413,000 after buying an additional 17,039 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of Savara during the 1st quarter worth approximately $466,000. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Savara by 12.5% during the 1st quarter. The Manufacturers Life Insurance Company now owns 11,550 shares of the company’s stock worth $85,000 after buying an additional 1,279 shares in the last quarter. 45.71% of the stock is currently owned by institutional investors.

NASDAQ:SVRA traded up $0.07 on Wednesday, hitting $10.57. The company’s stock had a trading volume of 155,571 shares, compared to its average volume of 211,067. The company has a quick ratio of 12.05, a current ratio of 12.05 and a debt-to-equity ratio of 0.24. The firm has a market capitalization of $378.72 million, a price-to-earnings ratio of -8.19 and a beta of 0.95. Savara has a one year low of $6.21 and a one year high of $14.06.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.05. Equities research analysts expect that Savara will post -1.63 EPS for the current year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Featured Article: Moving Average (MA)

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.